Together, we can START on a new path to treating Alzheimer’s disease.

START STUDY

The START (Synaptic Therapy Alzheimer’s Research Trial) Study is testing an investigational treatment to see if it can help slow memory loss caused by Alzheimer’s disease (AD). Scientists believe the investigational treatment, also called the study drug, works in a different way than other drugs used to treat AD. The drug does not have a name yet, so for now it is called CT1812. It comes in the form of a capsule, and it is not approved for use outside of a research study.

GOAL OF THE STUDY

The purpose of the START Study is to test CT1812 to see if it may potentially be used to treat people with early AD.